News for Supernus Pharmaceuticals, Inc. (0LB2.L)

Supernus Pharmaceuticals (SUPN) is set to release its first quarter 2025 financial results on May 6, 2025, after market close. The company will host a c

**media[603737]**

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc.

We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc.

Small-cap stocks in the US have been under pressure, with the Russell small cap index falling 10% from its November highs as of January 2025.

Supernus Pharmaceuticals Inc (SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, announced on March 4, 2025, that its Pre

ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. ( SUPN), a biopharmaceutical company focused on developing and commercializi

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Inc (SUPN) showcases a robust portfolio in CNS treatments, with a recent FDA approval expanding its market reach.Despite strong produc

Supernus Pharmaceuticals Inc (SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, announced on February 27, 2025, that its

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. ( SUPN), a biopharmaceutical company focused on developing and commercializin

Total Revenue (Q4 2024): $174.2 million, up from $164.3 million in Q4 2023.Net Product Sales (Q4 2024): $166.4 million.Operating Earnings (Q4 2024, GAAP): $21.

Feb 25, 2025 / 09:30PM GMTOperator Good afternoon and welcome to Supernus Pharmaceuticals fourth quarter and full-year 2024 financial results conference call. (

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Wednesday. Shares of Gentherm Incorporated THRM fell sharply in tod...

Utah-based Sintx Technologies, Inc. (SINT) is up over 87 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Shares of Global Blue Group Holding AG GB rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 f...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compare

**media[543769]**